Managing Director, MPM Capital
Patrick Baeuerle, Ph.D., joined MPM in 2015, and has since co-founded MPM oncology start-ups Harpoon, TCR², iOmx, Maverick and Cullinan. Previously, he was responsible for the development of BiTE antibody Blincyto®, which was approved in 2014 within three months by the U.S. FDA for therapy of relapsed/refractory acute lymphoblastic leukemia. He also spearheaded the BiTE technology, the industry’s leading T-cell engaging bispecific antibody platform.
Prior to joining MPM, Patrick served as Vice President, Research, and General Manager of Amgen Research Munich GmbH, where he oversaw translational sciences of BiTE antibodies. From 1998 to 2012, Patrick served as Chief Scientific Officer for Micromet, Inc., and earlier headed small molecule drug discovery at Tularik Inc., a publicly traded biotechnology company also acquired by Amgen (AMGN). From 1996-1998, he served as Professor and Chairman of Biochemistry and Molecular Biochemistry at the Medical Faculty of Freiburg University, Germany, where he did groundbreaking research on transcription factor NF-kappaB.
Patrick Baeuerle has published more than 235 PubMed-listed papers that have been cited more than 60,000 times to date. He has a Hirsh index of 117 and was rated Germany’s most frequently cited biomedical scientist of the decade (1990-1999), and among the top 50 worldwide (1990 to 1997). He holds a Ph.D. in biology from the University of Munich, and performed post-doctoral research with Dr. David Baltimore at the Whitehead Institute at the Massachusetts Institute of Technology. He is also an Honorary Professor of Immunology of the Medical Faculty at Munich University.